Repeated quorum shortfalls delay iSpecimen (NASDAQ: ISPC) 2025 annual meeting

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

iSpecimen Inc. has been unable to complete its 2025 Annual Meeting of Stockholders because not enough shareholders have participated to reach a quorum. The meeting, originally convened on December 31, 2025 and reconvened on January 23, 2026, February 13, 2026, and March 13, 2026, was adjourned each time for this reason.

The company now plans to reconvene the Annual Meeting on April 10, 2026 at 9:00 a.m. Eastern Time. The record date remains November 3, 2025, and the proposals to be voted on are unchanged from those described in the definitive proxy statement filed on November 21, 2025.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Understanding 8-K Material Events →

03/13/2026 - 05:00 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 13, 2026

iSpecimen Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40501		27-0480143
(State or other jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

8 Cabot Road, Suite 1800
Woburn, MA 01801

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (781) 301-6700

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ISPC		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On December 31, 2025, iSpecimen Inc. (the “Company”) convened its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). Because a quorum was not present, the Company adjourned the Annual Meeting to permit additional time for stockholders to vote on the proposals set forth in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 21, 2025 (the “Proxy Statement”).

The Annual Meeting was reconvened on January 23, 2026, February 13, 2026 and March 13, 2026. At each reconvened meeting, a quorum was not present and the Annual Meeting was adjourned.

The Company intends to reconvene the Annual Meeting on April 10, 2026 at 9:00 a.m. Eastern Time. The record date for determination of stockholders entitled to vote at the Annual Meeting remains November 3, 2025. No changes have been made to the proposals to be voted on at the Annual Meeting, which are described in the Proxy Statement.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 13, 2026

iSPECIMEN INC.

By:	/s/ Katharyn Field
	Name:	Katharyn Field
	Title:	Chief Executive Officer

Source: View Original Filing on SEC EDGAR

FAQ

Why did iSpecimen (ISPC) adjourn its 2025 Annual Meeting multiple times?

iSpecimen adjourned its 2025 Annual Meeting several times because a quorum of shareholders was not present. Without a quorum, the company cannot legally conduct business or vote on proposals outlined in its definitive proxy statement filed on November 21, 2025.

When will iSpecimen (ISPC) reconvene the 2025 Annual Meeting of Stockholders?

iSpecimen plans to reconvene the 2025 Annual Meeting on April 10, 2026 at 9:00 a.m. Eastern Time. This follows prior unsuccessful attempts on December 31, 2025, January 23, 2026, February 13, 2026, and March 13, 2026 due to lack of quorum.

Has iSpecimen (ISPC) changed the proposals for the 2025 Annual Meeting?

iSpecimen has not changed the proposals for the 2025 Annual Meeting. The matters to be voted on remain exactly as described in the company’s definitive proxy statement filed on November 21, 2025, despite the multiple adjournments for lack of quorum.

What is the record date for voting at iSpecimen’s 2025 Annual Meeting?

The record date for determining shareholders entitled to vote at iSpecimen’s 2025 Annual Meeting is November 3, 2025. Only stockholders of record on that date may vote when the meeting is reconvened on April 10, 2026, or any subsequent adjournment.

How many times has iSpecimen (ISPC) reconvened its 2025 Annual Meeting so far?

iSpecimen has reconvened its 2025 Annual Meeting three times so far, on January 23, 2026, February 13, 2026, and March 13, 2026. Each reconvened session was adjourned because a quorum of shareholders still was not present.

Where can investors find details on iSpecimen’s 2025 Annual Meeting proposals?

Investors can find details about iSpecimen’s 2025 Annual Meeting proposals in the company’s definitive proxy statement filed on November 21, 2025. The filing outlines each proposal that will be voted on when the meeting reconvenes on April 10, 2026.

Filing Exhibits & Attachments

3 documents